12:23 PM EST - IntelGenx Corp. : Announced that patient dosing has resumed in the ongoing Phase 2a clinical trial in patients with mild to moderate Alzheimer’s Disease under a previously amended protocol using higher doses of Montelukast VersaFilm. IntelGenx Corp.
shares T.IGX are trading up $0.005 at $0.44.